To promote and protect public health through science driven, comprehensive, strategies and actions that communicate potential risks about drug products and minimize exposure to unsafe, ineffective, or poor quality unapproved or misbranded drugs.
Using scientific, risk based strategies, and comprehensive compliance, we are global leaders in the effort to eliminate exposure to unapproved or misbranded drugs.
Office Director: Kalah Auchincloss, J.D., MPH (acting)
Deputy Office Director: Kathleen Anderson, Pharm.D.
Associate Director for Policy and Communication: Gail Bormel, J.D., R.Ph. (acting)
Associate Director for Program Management and Organizational Strategy: Akilah Green, RN, MS, RAC (acting)
Associate Director for Risk Science, Intelligence, and Prioritization: Meghan Murphy, Ph.D. (acting)
Senior Medical Advisor: Charles Lee, MD
Director, Division of Prescription Drugs: Gail Bormel, J.D., R.Ph. (acting)
Director, Division of Non-Prescription Drugs and Health Fraud: Elizabeth Miller, Pharm.D.
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Compliance
Office of Unapproved Drugs and Labeling Compliance
10903 New Hampshire Ave.
Silver Spring, MD 20993
Ph: (301) 796-3110
Fax: (301) 847-8745